SEC Company Response from Q32 Bio Inc. (QTTB) (CIK 0001661998) (QTTB) — Mar 23, 2018
Q32 Bio Inc. (QTTB) (CIK 0001661998)
Date: March 23, 2018 · CIK: 0001661998 · Accession: 0001193125-18-094014
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223409
Letter
Re: Homology Medicines, Inc.
March 23, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (as amended) (SEC File No. 333-223409)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Homology Medicines, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., New York City time, on March 27, 2018, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 870 copies of the Preliminary Prospectus dated March 19, 2018 through the date hereof, to underwriters, dealers, institutions and others, and are in the process of redistributing the preliminary prospectus dated March 23, 2018 (the “Preliminary Prospectus”) to those investors as well.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
March 23, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Homology Medicines, Inc.
Registration Statement on Form S-1 (as amended) (SEC File No. 333-223409)
Ladies and Gentlemen:
In connection with the above-referenced
Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Homology Medicines, Inc. that the effective date of the Registration Statement be
accelerated so that it will be declared effective at 4:00 p.m., New York City time, on March 27, 2018, or as soon thereafter as practicable.
Pursuant to
Rule 460 under the Act, please be advised that we have distributed approximately 870 copies of the Preliminary Prospectus dated March 19, 2018 through the date hereof, to underwriters, dealers, institutions and others, and are in the process of
redistributing the preliminary prospectus dated March 23, 2018 (the “Preliminary Prospectus”) to those investors as well.
In connection with
the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule
15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
COWEN AND COMPANY, LLC
EVERCORE GROUP L.L.C.
As Representatives of the several
underwriters
[SIGNATURE PAGES FOLLOW]
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
By:
/s/ Anurag Jindal
Name: Anurag Jindal
Title: Managing
Director
COWEN AND COMPANY, LLC
By:
/s/ Bill Follis
Name: Bill Follis
Title: Managing
Director
EVERCORE GROUP L.L.C.
By:
/s/ Maren Winnick
Name: Maren Winnick
Title: Managing
Director
As representatives of the several underwriters.
[Signature Page to Acceleration Request Letter]